文献速递白血病

成人急性髓系白血病中涉及11q23.3/KMT2A的重排:突变图谱与预后意义——HARMONY研究

Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.
PubMed 文献 · Leukemia · 2024-07-04

该研究从HARMONY急性髓系白血病数据库选取205例成人KMT2A重排患者,其中185例有二代测序突变信息。不同易位间总生存相似,包括t(9;11)(p21.3;q23.3)/KMT2A::MLLT3(p=0.756)。在强化治疗患者中,年龄>60岁、继发性急性髓系白血病、DNMT3A突变和KRAS突变是总生存的独立预后因素。

要点

  • 不同KMT2A易位类型间总生存无显著差异,包括t(9;11)(p21.3;q23.3)/KMT2A::MLLT3(p=0.756)。
  • 强化治疗患者中,年龄>60岁(HR 2.1)、继发性急性髓系白血病(HR 2.2)、DNMT3A突变(HR 2.1)和KRAS突变(HR 2.0)是总生存的独立预后因素。
  • 在<60岁新发急性髓系白血病患者中,KRAS或TP53突变者完全缓解率更低(50% vs 86%,p<0.001),总生存更差(中位7 vs 30个月,p<0.001)。

核心结论

  • 本研究强调成人KMT2A重排急性髓系白血病中突变模式的重要性,并为更准确的预后分层提供了新见解。

研究设计与样本

  • 从HARMONY急性髓系白血病数据库选取205例成人KMT2A重排患者,其中185例有基于面板的二代测序突变信息。

主要发现

  • 不同易位间总生存相似,包括t(9;11)(p21.3;q23.3)/KMT2A::MLLT3(p=0.756)。
  • 强化治疗患者中,年龄>60岁(HR 2.1,p=0.001)、继发性急性髓系白血病(HR 2.2,p=0.043)、DNMT3A突变(HR 2.1,p=0.047)和KRAS突变(HR 2.0,p=0.005)是总生存的独立预后因素。
  • 在<60岁新发急性髓系白血病患者中,KRAS或TP53突变者完全缓解率更低(50% vs 86%,p<0.001),总生存更差(中位7 vs 30个月,p<0.001)。
  • 首次完全缓解期接受异基因造血干细胞移植可改善总生存(p=0.003)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Balanced rearrangements involving the KMT2A gene (KMT2Ar) are recurrent genetic abnormalities in acute myeloid leukemia (AML), but there is lack of consensus regarding the prognostic impact of different fusion partners. Moreover, prognostic implications of gene mutations co-occurring with KMT2Ar are not established. From the HARMONY AML database 205 KMT2Ar adult patients were selected, 185 of whom had mutational information by a panel-based next-generation sequencing analysis. Overall survival (OS) was similar across the different translocations, including t(9;11)(p21.3;q23.3)/KMT2A::MLLT3 (p = 0.756). However, independent prognostic factors for OS in intensively treated patients were age >60 years (HR 2.1, p = 0.001), secondary AML (HR 2.2, p = 0.043), DNMT3A-mut (HR 2.1, p = 0.047) and KRAS-mut (HR 2.0, p = 0.005). In the subset of patients with de novo AML < 60 years, KRAS and TP53 were the prognostically most relevant mutated genes, as patients with a mutation of any of those two genes had a lower complete remission rate (50% vs 86%, p < 0.001) and inferior OS (median 7 vs 30 months, p < 0.001). Allogeneic hematopoietic stem cell transplantation in first complete remission was able to improve OS (p = 0.003). Our study highlights the importance of the mutational patterns in adult KMT2Ar AML and provides new insights into more accurate prognostic stratification of these patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hernández-Sánchez A, González T, Sobas M, et al. Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study. Leukemia. 2024. PMID: 38965370. doi:10.1038/s41375-024-02333-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。